Periarticular bone alterations in chronic antigen-induced arthritis: Free and liposome-encapsulated clodronate prevent loss of bone mass in the secondary spongiosa

Clinical Immunology

Volumn 90, Issue 1, 1999, Pages 79-88

  Oelzner, P ^a   Brauer R ^a   Henzgen, S ^a   Thoss, K ^a   Wunsche B ^a   Hersmann, G ^a   Abendroth, K ^a   Kinne, R W ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Antigen induced arthritis; Bone histomorphometry; Clodronate; Clodronate containing liposomes; Osteoporosis

Indexed keywords

CLODRONIC ACID; LIPOSOME;

ANIMAL EXPERIMENT; ARTHRITIS; ARTICLE; BONE ATROPHY; BONE MASS; BONE TURNOVER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUMBAR VERTEBRA; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

EID: 0344959539     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1998.4623     Document Type: Article

References (60)

1. Burmester G. R., Stuhlmüller B., Keyszer G., Kinne R. W. Mononuclear phagocytes and rheumatoid arthritis. Arthritis Rheum. 40:1997;5-18.
2. Bräuer R., Kette H., Henzgen S., Thoss K. Influence of cyclosporin A on cytokine levels in synovial fluid and serum of rats with antigen-induced arthritis. Agents Actions. 41:1994;96-98.
3. Schalkwijk J., van den Berg W. B., van de Putte L. B., Joosten L. A., van der Sluis M. Effects of experimental joint inflammation on bone marrow and periarticular bone: A study of two types of arthritis, using variable degrees of inflammation. Br. J. Exp. Pathol. 66:1985;435-444.
4. Deodhar A. A., Woolf A. D. Bone mass measurement and bone metabolism in rheumatoid arthritis: A review. Br. J. Rheumatol. 35:1996;309-322.
5. Aota S., Nakamura T., Suzuki K., Tanaka Y., Okazaki Y., Segawa Y., Miura M., Kikuchi S. Effects of indomethacin administration on bone turnover and bone mass in adjuvant-induced arthritis in rats. Calcif. Tissue Int. 59:1996;385-391.
6. Chang J. S., Quinn J. M., Demaziere A., Bulstrode C. J., Francis M. J., Duthie R. B., Athanasou N. A. Bone resorption by cells isolated from rheumatoid synovium. Ann. Rheum. Dis. 51:1992;1223-1229.
7. Kanis J. A., McCloskey E. V., Sirtori P., Kahn S., Fern D., Eyres K., Aaron J., Beneton M. N. Rationale for the use of clodronate in osteoporosis. Osteoporosis Int. 3:1995;S23-28.
8. Plosker G. L., Goa K. L. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 47:1994;945-982.
9. Selander K. S., Mönkkönen J., Karhukorpi E. K., Harkonen P., Hannuniemi R., Väänenen H. K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol. Pharmacol. 50:1996;1127-1138.
10. Hughes D. E., Wright K. R., Uy H. L., Sasaki A., Yoneda T., Roodman G. D., Mundy G. R., Boyce B. F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. 10:1995;1478-1487.
11. Schmidt-Weber C. B., Rittig M., Buchner E., Hauser I., Schmidt I., Palombo-Kinne E., Emmrich F., Kinne R. W. Apoptotic cell death in activated monocytes following incorporation of clodronate-liposomes. J. Leukocyte Biol. 60:1996;230-244.
12. Claasen I., van Rooijen N., Claasen E. A new method for removal of mononuclear phagocytes from heterogeneous cell populations in vitro, using the liposome-mediated macrophage suicide technique. J. Immunol. Methods. 134:1990;153-161.
13. Buiting A. M. J., van Rooijen N. Liposome mediated depletion of macrophages: An approach for fundamental studies. J. Drug Targeting. 2:1994;357-362.
14. Van Rooijen N., Sanders A. Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications. J. Immunol. Methods. 174:1994;83-93.
15. Camilleri J. P., Williams A. S., Amos N., Douglas-Jones A. G., Love W. G., Williams B. D. The effect of free and liposome-encapsulated clodronate on the hepatic mononuclear phagocyte system in the rat. Clin. Exp. Immunol. 99:1995;269-275.
16. Camilleri J. P., Williams A. S., Amos N., Douglas-Jones A. G., Love W. G., Williams B. D. Methods for assessing splenic macrophage depletion by liposome encapsulated clodronate. Inflamm. Res. 44:1995;152-157.
17. Van Rooijen N., Sanders A. Kupffer cell depletion by liposome-delivered drugs: Comparative activity of intracellular clodronate, propamidine, and ethylenediaminetetraacetic acid. Hepatology. 23:1996;1239-1243.
18. Kinne R. W., Schmidt-Weber C. B., Hoppe R., Buchner E., Palombo-Kinne E., Nürnberg E., Emmrich F. Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum. 38:1995;1777-1790.
19. Kinne R. W., Schmidt C. B., Buchner E., Hoppe R., Nürnberg E., Emmrich F. Treatment of rat arthritides with clodronate-containing liposomes. Scand. J. Rheumatol. 101:1995;91-97.
20. Baron R. Anatomy and ultrastructure of bone. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 1993;Raven Press, New York. p. 3-9.
21. Claasen E. Post-formation fluorescent labelling of liposomal membranes. In vivo detection, localisation and kinetics. J. Immunol. Methods. 147:1992;231-240.
22. Delling G. Endocrine Bone Diseases. 1975;Fischer, Stuttgart. p. 3-33.
23. Ma Y. F., Jee W. S., Ke H. Z., Lin B. Y., Liang X. G., Li M., Yamamoto N. Human parathyroid hormone (1-38) restores cancellous bone to the immobilized, osteopenic proximal tibial metaphysis in rats. J. Bone Miner. Res. 10:1995;496-505.
24. Murakami H., Nakamura T., Tsurukami H., Abe M., Barbier A., Suzuki K. Effects of tiludronate on bone mass, structure and turnover at the epiphyseal, primary and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy. J. Bone Miner. Res. 9:1994;1355-1364.
25. Malluche, H. H. Faugere, M. C. Atlas of Mineralized Bone Histology, Karger, Basel, 1986.
26. Parfitt A. M., Drezner M. K., Glorieux F. H., Kanis J. A., Malluche H., Meunier P. J., Ott S. M., Recker R. R. Bone histomorphometry: Standardization of nomenclature, symbols and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2:1987;595-610.
27. Beaudrieul J., Mbalaviele G., Cohen-Solal M., Morieux C., De Vernejoul M. C., Orcel P. Short-term local injections of transforming growth factor-beta 1 decrease ovariectomy-stimulated osteoclastic resorption in vivo in rats. J. Bone Miner. Res. 10:1995;971-977.
28. Österman T., Kippo K., Lauren L., Hannuniemi R., Sellman R. Effect of clodronate on established collagen-induced arthritis in rat. Inflamm. Res. 44:1995;258-263.
29. Shimizu S., Shiozawa S., Shiozawa K., Imura S., Fujita T. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum. 28:1985;25-31.
30. Kröger H., Arnala I., Rehnberg V., Hamalainen M., Alhava E. Histomorphometry of periarticular bone in rheumatoid arthritis. Ann. Chir. Gynaecol. 83:1994;56-62.
31. Kotake S., Higaki M., Sato K., Himeno S., Morita H., Kim K. J., Nara N., Miyasaka N., Nishioka K., Kashiwazaki S. Detection of myeloid precursors (granulocyte/macrophage colony forming units) in the bone marrow adjacent to rheumatoid arthritis joints. J. Rheumatol. 19:1992;1511-1516.
32. Tanabe M., Ochi T., Tomita T., Suzuki R., Sakata T., Shimaoka Y., Nakagawa S., Ono K. Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J. Rheumatol. 21:1994;830-835.
33. Hukkanen M., Hughes F. J., Buttery L. D., Gross S. S., Evans T. J., Seddon S., Riveros-Moreno V., Macintyre I., Polak J. M. Cytokine-stimulated expression of inducible nitric oxide synthase by mouse, rat, and human osteoblast-like cells and its functional role in osteoblast metabolic activity. Endocrinology. 136:1995;5445-5453.
34. Rico H., Amo C., Revilla M., Arribas I., Gonzalez-Riola J., Villa L. F., Rodriguez-Puyol M. Etidronate versus clodronate in the prevention of postovariectomy bone loss: An experimental study in rats. Clin. Exp. Rheumatol. 12:1994;301-304.
35. Kippo K., Hannuniemi R., Lauren L., Peng Z., Isaksson P., Virtamo T., Österman T., Pasanen I., Sellman R., Väänenen H. K. Clodronate prevents bone loss in aged ovariectomized rats. Calcif. Tissue Int. 61:1997;151-157.
36. Kippo K., Hannuniemi R., Isaksson P., Lauren L., Österman T., Peng Z., Tuukkanen J., Kuurtamo P., Väänenen H. K., Sellman R. Clodronate prevents osteopenia and loss of trabecular connectivity in estrogen-deficient rats. J. Bone Miner. Res. 13:1998;287-296.
37. Österman T., Lauren L., Kuurtamo P., Hannuniemi R., Isaksson P., Kippo K., Peng Z., Väänenen H. K., Sellman R. The effect of orally administered clodronate on bone mineral density and bone geometry in ovariectomized rats. J. Pharmacol. Exp. Ther. 284:1998;312-316.
38. Lepola V., Jalovaara P., Vaananen K. The influence of clodronate on the torsonal strength of the growing rat tibia in immobilization osteoporosis. Bone. 15:1994;367-371.
39. Antic V. N., Fleisch H., Muhlbauer R. C. Effect of bisphosphonates on the increase in bone resorption induced by a low calcium diet. Calcif. Tissue Int. 58:1996;443-448.
40. Österman T., Kippo K., Lauren L., Hannuniemi R., Sellman R. Effect of clodronate on established adjuvant arthritis. Rheumatol. Int. 14:1994;139-147.
41. Österman T., Kippo K., Lauren L., Pasanen I., Hannuniemi R., Sellman R. A comparison of clodronate and indomethacin in the treatment of adjuvant arthritis. Inflamm. Res. 46:1997;79-85.
42. Österman T., Virtamo T., Lauren L., Kippo K., Pasanen I., Hannuniemi R., Vaananen K., Sellman R. Slow-release clodronate in prevention of inflammation and bone loss associated with adjuvant arthritis. J. Pharmacol. Exp. Ther. 280:1997;1001-1007.
43. Fleisch H. A. Bisphosphonates: preclinical aspects and use in osteoporosis. Ann. Med. 29:1997;55-62.
44. Khokher M. A., Dandona P. Diphosphonates inhibit human osteoblast secretion and proliferation. Metabolism. 38:1989;184-187.
45. Elomaa I., Risteli L., Laakso M., Lahtinen R., Virkkunen P., Risteli J. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Eur. J. Cancer. 32:1996;1166-1170.
46. Goziotis A., Sukhu B., Torontali M., Dowhaniuk M., Tenenbaum C. Effects of bisphosphonates APD and HEBP on bone metabolism in vitro. Bone. 16:1995;317S-327S.
47. Giuliani N., Pedrazzon M., Passeri G., Girasol G. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. Scand. J. Rheumatol. 27:1998;38-41.
48. Weryha G., Leclerc J. Paracrine regulation of bone remodeling. Horm. Res. 43:1995;69-75.
49. Suzuki Y., Tanihara M., Ichikawa Y., Osanai A., Nakagawa M., Ide M., Mizushima Y. Periarticular osteopenia in adjuvant induced arthritis: Role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells. Ann. Rheum. Dis. 54:1995;484-490.
50. Fujikawa Y., Sabokbar A., Neale S., Athanasou N. A. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. Ann. Rheum. Dis. 55:1996;816-822.
51. Kotake S., Sato K., Kim K. J., Takahashi N., Udagawa N., Nakamura I., Yamaguchi A., Kishimoto T., Suda T., Kashiwazaki S. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J. Bone Miner. Res. 11:1996;88-95.
52. Toritsuka Y., Nakamura N., Lee S. B., Hashimoto J., Yasui N., Shino K., Ochi T. Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis. J. Rheumatol. 24:1997;1690-1696.
53. Hayashida K., Ochi T., Fujimoto M., Owaki H., Shimaoka Y., Ono K., Matsumoto K. Bone marrow changes in adjuvant-induced and collagen-induced arthritis. Interleukin-1 and interleukin-6 activity and abnormal myelopoiesis. Arthritis Rheum. 35:1992;241-245.
54. Seitz M., Zwicker M., Pichler W., Gerber N. Activation and differentiation of myelomonocytic cells in rheumatoid arthritis and healthy individuals - Evidence for antagonistic in vitro regulation by interferon-gamma and tumor necrosis factor alpha, granulocyte monocyte colony stimulating factor and interleukin 1. J. Rheumatol. 19:1992;1038-1044.
55. Mönkkönen J., Taskinen M., Auriola S. O. K., Urtti A. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound and free bisphosphonates in vitro. J. Drug Targeting. 2:1994;299-308.
56. Österman T., Virtamo T., Kippo K., Lauren L., Pasanen I., Hannuniemi R., Sellman R. Distribution of clodronate in the bone of adult rats and its effects on trabecular and cortical bone. J. Pharmacol. Exp. Ther. 280:1997;1051-1056.
57. Dave J., Patel H. M. Differentiation in hepatic and splenic phagocytic activity during reticuloendothelial blockade with cholesterol-free and cholesterol-rich liposomes. Biochim. Biophys. Acta. 888:1986;184-190.
58. Naito M., Kudo I., Mukai-Sato Y., Tsushima S., Nomura H., Nojima S., Inoue K. Activation of mouse peritoneal macrophages by synthetic glyceroglycolipid liposomes. Cancer Immunol. Immunother. 24:1987;158-164.
59. Wassef N. M., Roerdink F., Richardson E. C., Alving C. R. Suppression of phagocytic function and phospholipid metabolism in macrophages by phosphatidylinositol liposomes. Proc. Natl. Acad. Sci. USA. 81:1984;2655-2659.
60. Eggelmeijer F., Papapoulos S. E., van Paasen H. C., Dijkmans B. A., Breedveld F. C. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: A double blind placebo controlled study. J. Rheumatol. 21:1994;2016-2020.